vs
Side-by-side financial comparison of Essex Property Trust (ESS) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $479.6M, roughly 1.2× Essex Property Trust). EXELIXIS, INC. runs the higher net margin — 40.8% vs 17.9%, a 23.0% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs 5.5%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 6.0%).
Essex Property Trust is a publicly traded real estate investment trust that invests in apartments in California and in the Seattle metropolitan area.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
ESS vs EXEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $479.6M | $598.7M |
| Net Profit | $85.7M | $244.5M |
| Gross Margin | 70.0% | 95.6% |
| Operating Margin | 31.7% | 39.3% |
| Net Margin | 17.9% | 40.8% |
| Revenue YoY | 5.5% | 5.6% |
| Net Profit YoY | -71.6% | 74.8% |
| EPS (diluted) | $1.24 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | $479.6M | $597.8M | ||
| Q3 25 | $473.3M | $568.3M | ||
| Q2 25 | $469.8M | $555.4M | ||
| Q1 25 | $464.6M | $566.8M | ||
| Q4 24 | $454.5M | — | ||
| Q3 24 | $450.7M | $539.5M | ||
| Q2 24 | $442.4M | $637.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | $85.7M | $193.6M | ||
| Q3 25 | $172.7M | $184.8M | ||
| Q2 25 | $231.5M | $159.6M | ||
| Q1 25 | $212.8M | $139.9M | ||
| Q4 24 | $301.7M | — | ||
| Q3 24 | $125.5M | $118.0M | ||
| Q2 24 | $99.0M | $226.1M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | 70.0% | 96.9% | ||
| Q3 25 | 69.2% | 96.6% | ||
| Q2 25 | 70.7% | 96.5% | ||
| Q1 25 | 69.6% | 96.5% | ||
| Q4 24 | 70.0% | — | ||
| Q3 24 | 69.5% | 96.8% | ||
| Q2 24 | 70.8% | 97.2% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | 31.7% | 39.6% | ||
| Q3 25 | 44.5% | 37.6% | ||
| Q2 25 | 59.5% | 33.6% | ||
| Q1 25 | 55.3% | 28.8% | ||
| Q4 24 | 67.0% | — | ||
| Q3 24 | 28.6% | 25.2% | ||
| Q2 24 | 31.1% | 43.3% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | 17.9% | 32.4% | ||
| Q3 25 | 36.5% | 32.5% | ||
| Q2 25 | 49.3% | 28.7% | ||
| Q1 25 | 45.8% | 24.7% | ||
| Q4 24 | 66.4% | — | ||
| Q3 24 | 27.8% | 21.9% | ||
| Q2 24 | 22.4% | 35.5% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $1.24 | $0.69 | ||
| Q3 25 | $2.56 | $0.65 | ||
| Q2 25 | $3.44 | $0.55 | ||
| Q1 25 | $3.16 | $0.47 | ||
| Q4 24 | $4.00 | — | ||
| Q3 24 | $1.84 | $0.40 | ||
| Q2 24 | $1.45 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $76.2M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.5B | $2.2B |
| Total Assets | $13.2B | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $76.2M | $988.5M | ||
| Q3 25 | $66.0M | $791.1M | ||
| Q2 25 | $58.7M | $1.0B | ||
| Q1 25 | $98.7M | $1.1B | ||
| Q4 24 | $66.8M | — | ||
| Q3 24 | $71.3M | $1.2B | ||
| Q2 24 | $55.2M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.2B | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $5.5B | $2.2B | ||
| Q3 25 | $5.6B | $2.0B | ||
| Q2 25 | $5.6B | $2.1B | ||
| Q1 25 | $5.6B | $2.2B | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | $5.4B | $2.3B | ||
| Q2 24 | $5.5B | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $13.2B | $2.8B | ||
| Q3 25 | $13.2B | $2.7B | ||
| Q2 25 | $13.2B | $2.8B | ||
| Q1 25 | $13.2B | $2.9B | ||
| Q4 24 | $12.9B | — | ||
| Q3 24 | $12.6B | $3.0B | ||
| Q2 24 | $12.5B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.1B | $333.5M |
| Free Cash FlowOCF − Capex | — | $332.4M |
| FCF MarginFCF / Revenue | — | 55.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 12.53× | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | — | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $1.1B | $290.3M | ||
| Q3 25 | $342.6M | $49.0M | ||
| Q2 25 | $216.1M | $211.4M | ||
| Q1 25 | $281.5M | $240.3M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $316.2M | $271.3M | ||
| Q2 24 | $218.9M | $119.5M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | — | $113.0M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 17.7% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | 12.53× | 1.50× | ||
| Q3 25 | 1.98× | 0.27× | ||
| Q2 25 | 0.93× | 1.32× | ||
| Q1 25 | 1.32× | 1.72× | ||
| Q4 24 | 3.54× | — | ||
| Q3 24 | 2.52× | 2.30× | ||
| Q2 24 | 2.21× | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESS
Segment breakdown not available.
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
